{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:34:26Z","timestamp":1758904466803,"version":"3.37.3"},"reference-count":21,"publisher":"Informa UK Limited","issue":"9","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA102713-01"],"award-info":[{"award-number":["1R01CA102713-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.1080\/14740338.2023.2245748","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T17:47:17Z","timestamp":1692380837000},"page":"783-788","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["United States\u2019 regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism"],"prefix":"10.1080","volume":"22","author":[{"given":"Charles L.","family":"Bennett","sequence":"first","affiliation":[{"name":"The SmartState Center for Medication Safety and Efficacy and the Department of Family Medicine, the University of South Carolina, Columbia, South Carolina, (CLB, PG, KK, CN, WJH), the City of Hope National Cancer Institute Designated Comprehensive Cancer Center, Duarte, California (CLB, SJR), Imperial College London (RPG), the University of Nebraska College of Medicine\/Omaha Omaha, Nebraska (JOA), Duarte, California (CLB)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Georgantopoulos","sequence":"additional","affiliation":[{"name":"The SmartState Center for Medication Safety and Efficacy and the Department of Family Medicine, the University of South Carolina, Columbia, South Carolina, (CLB, PG, KK, CN, WJH), the City of Hope National Cancer Institute Designated Comprehensive Cancer Center, Duarte, California (CLB, SJR), Imperial College London (RPG), the University of Nebraska College of Medicine\/Omaha Omaha, Nebraska (JOA), Duarte, California (CLB)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"The SmartState Center for Medication Safety and Efficacy and the Department of Family Medicine, the University of South Carolina, Columbia, South Carolina, (CLB, PG, KK, CN, WJH), the City of Hope National Cancer Institute Designated Comprehensive Cancer Center, Duarte, California (CLB, SJR), Imperial College London (RPG), the University of Nebraska College of Medicine\/Omaha Omaha, Nebraska (JOA), Duarte, California (CLB)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Knopf","sequence":"additional","affiliation":[{"name":"The SmartState Center for Medication Safety and Efficacy and the Department of Family Medicine, the University of South Carolina, Columbia, South Carolina, (CLB, PG, KK, CN, WJH), the City of Hope National Cancer Institute Designated Comprehensive Cancer Center, Duarte, California (CLB, SJR), Imperial College London (RPG), the University of Nebraska College of Medicine\/Omaha Omaha, Nebraska (JOA), Duarte, California (CLB)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J","family":"Hrushesky","sequence":"additional","affiliation":[{"name":"The SmartState Center for Medication Safety and Efficacy and the Department of Family Medicine, the University of South Carolina, Columbia, South Carolina, (CLB, PG, KK, CN, WJH), the City of Hope National Cancer Institute Designated Comprehensive Cancer Center, Duarte, California (CLB, SJR), Imperial College London (RPG), the University of Nebraska College of Medicine\/Omaha Omaha, Nebraska (JOA), Duarte, California (CLB)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[{"name":"The SmartState Center for Medication Safety and Efficacy and the Department of Family Medicine, the University of South Carolina, Columbia, South Carolina, (CLB, PG, KK, CN, WJH), the City of Hope National Cancer Institute Designated Comprehensive Cancer Center, Duarte, California (CLB, SJR), Imperial College London (RPG), the University of Nebraska College of Medicine\/Omaha Omaha, Nebraska (JOA), Duarte, California (CLB)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"The SmartState Center for Medication Safety and Efficacy and the Department of Family Medicine, the University of South Carolina, Columbia, South Carolina, (CLB, PG, KK, CN, WJH), the City of Hope National Cancer Institute Designated Comprehensive Cancer Center, Duarte, California (CLB, SJR), Imperial College London (RPG), the University of Nebraska College of Medicine\/Omaha Omaha, Nebraska (JOA), Duarte, California (CLB)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1097\/HP.0000000000000279"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph9082894"},{"key":"#cr-split#-cit0003.1","unstructured":"FDA approves neupogen for treatment of patients with radiation-induced myelosuppression following a radiological\/nuclear accident. Press Release. [updated 2023 Apr 8"},{"key":"#cr-split#-cit0003.2","unstructured":"cited Mar 30, 2015]. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/about-mcmi\/fda-approves-radiation-medical-countermeasure#:~:text=On%20March%2030%2C%202015%2C%20FDA,internal%20organs%2C%20including%20bone%20marrow"},{"key":"cit0004","unstructured":"FDA approves Leukine for Acute Radiation Syndrome. Mar 29, 2018. Press Release. [cited 2023 Apr 8]. https:\/\/www.fda.gov\/media\/112441\/download."},{"key":"#cr-split#-cit0005.1","unstructured":"Global Biodefense. Neulasta approved for treatment of acute radiation syndrome. [updated 2023 Aug 4"},{"key":"#cr-split#-cit0005.2","unstructured":"cited Aug 4, 2015]. https:\/\/globalbiodefense.com\/2015\/12\/03\/pegfilgrastim-neulasta-acute-radiation-syndrome\/"},{"key":"cit0006","unstructured":"Amgen Inc. Product label for romiplsotin. [cit 2023 Aug 4] https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125268s167lbl.pdf."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03400050067029"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1714289"},{"key":"cit0009","unstructured":"HHS purchases drug for use in radiological and nuclear emergencies [press release]. US Department Of Health & Human Services. [updated 2023 Aug 7; cited Oct 4, 2022]. https:\/\/aspr.hhs.gov\/newsroom\/Pages\/ARS-Oct2022.aspx"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01320"},{"key":"cit0011","unstructured":"FDA news release. FDA approves new treatment for inhalation anthrax. [updated 2023 Aug 4; cited Mar 21, 2016. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-inhalation-anthrax"},{"key":"cit0012","unstructured":"Product insert for obiltoxaximab. Elusys therapeutics, inc. [cited 2023 Apr 8]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125509s015lbl.pdf."},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.13"},{"key":"cit0014","unstructured":"product insert for anthrax immune globulin. Cangene Corporation. [cited 2023 Jun 6 6]. https:\/\/www.fda.gov\/media\/91577\/download"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020353"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2011.0105"},{"key":"cit0017","unstructured":"API Sourcing: The Supply Side for US-Marketed Drugs - DCAT Value Chain Insights (dcatvci.org) 2019. [cited Jun 6, 2023]. https:\/\/www.dcatvci.org\/features\/global-api-sourcing-which-countries-lead\/"},{"journal-title":"Testimony of Janet Woodcock MD, Director, Center for Drug Evaluation and Research, FDA, Department of Health and Human Services before the Subcommittee on Oversight and Investigations, Committee on Energy Commerce, United States House of Representatives","year":"2019","author":"US FDA","key":"cit0018"},{"journal-title":"Draft Guidance for Industry","year":"2023","author":"US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research","key":"cit0019"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2245748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T09:09:07Z","timestamp":1694596147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2245748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,2]]}},"alternative-id":["10.1080\/14740338.2023.2245748"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2245748","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"type":"print","value":"1474-0338"},{"type":"electronic","value":"1744-764X"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}